Company Overview - Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities [2] - The company's products assist in scientific investigations into biological processes, disease progression, drug discovery, and accurate clinical tests and diagnoses [2] - Bio-Techne has a portfolio of hundreds of thousands of products and generated approximately $1.2 billion in net sales in fiscal 2024 [2] - The company employs approximately 3,100 people worldwide [2] Upcoming Event - Kim Kelderman, President and CEO of Bio-Techne, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 10:30 a.m. PST [1] - A live webcast of the presentation will be available on Bio-Techne's Investor Relations website [1]

Guangzhou, Dec. 19, 2024 (GLOBE NEWSWIRE) -- YSX TECH. CO., LTD (the “Company” or “YSXT”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 Class A ordinary shares (the “Ordinary Shares”) at a public offering price of $4.00 per share for total gross proceeds of approximately $5,000,00 ...

MINNEAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and development processes. The companies plan to combine their complementary expertise on charge separation (Bio-Techne's MauriceFlex™ System) and liquid chromatography mass spectrometry (BioAccord™ LC-MS S ...

ST. PAUL, Minn., Dec. 18, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant. Moonlight Bio's G-Rex® Grant will expedite process development and IND-enabling studies of their lead CAR T cell therapy for the treatment of solid tumors."We are grateful to receive a G-Rex Grant to support the advancement of our lead CAR T asset into the clinic in a platform that ...

Bio-Techne Corp. (TECH) has launched a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer.The research-use-only assay, which includes a qPCR detection kit and an isolation kit for cell-free DNA and exosomal RNA, will also be featured at the ongoing San Antonio Breast Cancer Symposium. The latest development is expected to bolster the company’s Diagnostics and Spatial Biology segmen ...

Core Insights - Bio-Techne (TECH) is advancing in its four growth verticals, which are expected to drive growth in upcoming quarters [1] - The company has achieved ISO 13485 certification and is now pursuing clinical diagnostic opportunities on the Ella platform [1][6] - Acquisitions remain a key strategy for Bio-Techne to expand its portfolio and enter adjacent markets, despite facing macroeconomic challenges and competitive pressures [1][7][10] Growth Verticals - The Proteomics Analytical Instrumentation franchise, under the ProteinSimple brand, reported mid-single-digit growth in fiscal 2024, driven by SimplePlex and SimpleWestern products [4] - The Cell and Gene Therapy vertical is experiencing growth due to strong biotech funding and customer additions [4] - The Diagnostics and Spatial Biology vertical is showing solid growth, with positive responses from newly added RNAscope assays [5] - The Molecular Diagnostics vertical achieved nearly 40% growth in the first quarter of fiscal 2025, particularly in the ExoDx prostate test and Asuragen kit business [5] Ella Platform and Strategic Acquisitions - The Ella platform, following ISO 13485 certification, is gaining traction in clinical diagnostics, particularly for cell and gene therapy applications [6] - Bio-Techne's acquisition of Lunaphore is aimed at scaling up instrument production capacity to meet demand [7] - The company has made a 19.9% investment in Wilson Wolf and plans to acquire the remaining ownership by the end of calendar year 2027 [8] Challenges - The macroeconomic environment, especially in Asia Pacific and Europe, is leading to increased raw material and labor costs, which may impact operations through 2024 [10] - Bio-Techne faces intense competition from both large global companies and smaller niche players, leading to pricing pressures [11] Financial Performance - Over the past year, Bio-Techne's shares have increased by 15.4%, outperforming the industry growth of 0.9% [2] - The company's market capitalization stands at $11.97 billion, with fiscal 2025 earnings estimates recently adjusted down by 6 cents to $1.92 [2][12] - Revenue estimates for fiscal 2025 are projected at $1.22 billion, indicating a 5.6% increase from the previous year [12]

WEST SACRAMENTO, Calif., Nov. 25, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (NASDAQ: TECH).GeminiBio has a 39-year history of supporting FBS customers. With this agreement, GeminiBio builds ...

Core Insights - Bio-Techne (TECH) reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, exceeding the Zacks Consensus Estimate by 10.5% and surpassing the year-ago figure by a penny [1][10] - The company registered net sales of $289.5 million, reflecting a 5% year-over-year increase on a reported basis and a 4% increase on an organic basis, also exceeding the Zacks Consensus Estimate by 3.1% [3][10] Financial Performance - GAAP EPS was reported at 21 cents, down from 31 cents in the prior-year quarter [2] - Gross profit decreased by 1.2% to $183 million, with gross margin contracting by 364 basis points to 63.2% due to a 16% rise in cost of sales [6] - Selling, general and administrative expenses rose by 13.1% to $119.2 million, while research and development expenses totaled $23.8 million, down 0.5% year over year [6] Segment Performance - In the Protein Sciences segment, revenues were $204.5 million, flat year over year, with a 1% organic increase [4] - The Diagnostics and Genomics segment saw a 14% increase in sales to $72.8 million, with a 14% organic growth as well [5] - The operating margin for the Protein Sciences segment contracted by 380 basis points to 39.4%, while the Diagnostics and Spatial Biology segment's operating margin increased by 440 basis points to 5.1% [7] Capital Structure - At the end of the first quarter, Bio-Techne had cash and equivalents of $187.5 million, up from $152.9 million at the end of fiscal 2024, while long-term debt obligations decreased to $300 million from $319 million [8] Cash Flow - Cumulative net cash provided by operating activities was $63.9 million, compared to $59.4 million a year ago [9] Management Commentary - Management indicated that the start to fiscal 2025 was consistent with expectations, highlighting continued momentum in the Diagnostics & Spatial Biology segment and strong results in the cell and gene therapy business [11]

Techne (TECH) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 10.53%. A quarter ago, it was expected that this maker of medical testing and diagnostic products would post earnings of $0.51 per share when it actually produced earnings of $0.49, delivering a surprise of -3.92%. Over the ...

PARSIPPANY, NJ – October 21, 2024, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Lincoln Educational Services Corporation (NASDAQ: LINC), a national leader in specialized technical training for more than 75 years, has partnered with Hyundai Motor America (HMA) & Genesis Motor America (GMA) to launch two new employer-specific training programs. These programs will supplement Lincoln Tech’s Automotive Service Technology programs across the country and help students build skills on Hyundai/Genesis equipment and systems, w ...